Literature DB >> 20698214

Clinicopathological study of colorectal cancer occurring in patients with ulcerative colitis: results from a single hospital in Japan.

Takayoshi Fujita1, Takafumi Ando, Osamu Watanabe, Motofusa Hasegawa, Nobuyuki Miyake, Shinya Kondo, Tsuyoshi Kato, Kazuhiro Ishiguro, Masanao Nakamura, Ryoji Miyahara, Naoki Ohmiya, Yasumasa Niwa, Hidemi Goto.   

Abstract

BACKGROUND/AIMS: Colorectal cancer (CRC) was first recognized as a complication of ulcerative colitis (UC) in 1925, and the increased risk has since been confirmed in a multitude of epidemiological studies. To our knowledge, however, all of these studies have been conducted in Western countries. The aim of this study was to identify the clinicopathological features of ulcerative colitis-related CRC in a consecutive series of patients at a single hospital in central Japan.
METHODOLOGY: 314 (170 males, 144 females, mean age 30) consecutive patients diagnosed with ulcerative colitis were enrolled and investigated for the development of CRC. 240 patients had relapsing-remitting disease, 54 had chronic continuous disease, 16 had experienced one attack only, 2 had the acute fulminating type, and 2 were unknown. With regard to disease extension, 181 cases were of the pan-colitis type, 84 were left-sided colitis, and 42 were proctitis. Two patients (1%) had a family history of colorectal cancer and 45 (14%) were past or current smokers.
RESULTS: Colorectal cancer developed in seven patients (male to female ratio of 1:6), which was 2.2% of the total. Average age at the onset of ulcerative colitis was 28 years. Average age at the onset of cancer was 44 years, and average duration of UC at cancer onset was 192 months. Ulcerative colitis was of the pancolitis type in all cases. Three patients (43%) showed the relapse-remitting type and four (57%) the chronic continuing type. Three patients (43%) had a family history of cancer, in particular colorectal cancer in one patient (14%). None of the patients had a history of smoking. The histological type of cancer was well differentiated tubular adenocarcinoma in three patients (43%) and poorly differentiated adenocarcinoma in three patients (43%) each, and endocrine cell carcinoma in one (14%).
CONCLUSIONS: In this group of Japanese patients, development of colorectal cancer was more likely to occur in patients with ulcerative colitis that was long-standing, and more extensive than left-sided colitis, particularly in those with a family history of colorectal cancer, inflammatory polyps, or dysplasia. CRCs in our patients with UC were often poorly differentiated and had a poor prognosis.

Entities:  

Mesh:

Year:  2010        PMID: 20698214

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

Review 1.  Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis.

Authors:  Sawan Bopanna; Ashwin N Ananthakrishnan; Saurabh Kedia; Vijay Yajnik; Vineet Ahuja
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-02-21

2.  Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives.

Authors:  Soo Jung Park; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 3.  Changing epidemiological trends of inflammatory bowel disease in Asia.

Authors:  Wee Khoon Ng; Sunny H Wong; Siew C Ng
Journal:  Intest Res       Date:  2016-04-27

Review 4.  Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.

Authors:  Taku Kobayashi; Tadakazu Hisamatsu; Yasuo Suzuki; Haruhiko Ogata; Akira Andoh; Toshimitsu Araki; Ryota Hokari; Hideki Iijima; Hiroki Ikeuchi; Yoh Ishiguro; Shingo Kato; Reiko Kunisaki; Takayuki Matsumoto; Satoshi Motoya; Masakazu Nagahori; Shiro Nakamura; Hiroshi Nakase; Tomoyuki Tsujikawa; Makoto Sasaki; Kaoru Yokoyama; Naoki Yoshimura; Kenji Watanabe; Miiko Katafuchi; Mamoru Watanabe; Toshifumi Hibi
Journal:  Intest Res       Date:  2018-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.